| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financing at 40% premium to market price provides near-term bridge to anticipated milestones
CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares.
Under the terms of the agreement, NeuroSense will issue 333,334 ordinary shares at a purchase price of $1.50 per share, representing a 40% premium to the closing price of the Company's ordinary shares on September 3, 2025. The private placement is expected to close on September 8, 2025, subject to customary conditions.
Proceeds from the financing are expected to be used for general corporate purposes and working capital.
Posted In: NRSN
